KORU Medical Systems, Inc.
KORU Medical develops, manufactures and commercializes large-volume subcutaneous infusion systems for patients and healthcare professionals, primarily for drug delivery. Its FREEDOM Infusion System includes the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The system is used to administer therapies including immunoglobulin for Primary Immunodeficiency Diseases and Chronic Inflammatory Demyelinating Polyneuropathy, as well as selected other drugs. KORU Medical makes money from sales of drivers, tubing and needles in the United States and Canada and internationally, and from products and non-recurring engineering services for biopharmaceutical companies’ feasibility studies and clinical trials. It sells through direct sales and medical device distributors to pharmaceutical companies, specialty pharmacies and home infusion providers. KORU Medical is headquartered in Mahwah, New Jersey, where it manufactures all of its pump product volume and a portion of its consumables.
No SEC Form 4 filings for $KRMD in the last 30 days.
See all $KRMD insider activity →KORU Medical Systems (NYSE:KORU) reported Q3 2026 revenue of $11.6M, up 11% YoY, with gross margin expanding to 65.2%. Net income turned positive at $218K, exceeding expectations. Shares rose 8.23% after-hours. The company is expanding into new markets and therapies, with improved profitability and raised full-year margin guidance.
KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA MAHWAH, NJ – November 10, 2026 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical t
KALBERMATTEN ADAM R (Chief Commercial Officer) purchased 32,000 shares of KORU Medical Systems, Inc. (KRMD) at $3.16 ($0.10M total) on 2026-09-08.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning KRMD (KORU Medical Systems, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent KRMD coverage spans earnings, insider activity and financial news.
KORU Medical Systems (NYSE:KORU) reported Q3 2026 revenue of $11.6M, up 11% YoY, with gross margin expanding to 65.2%. Net income turned positive at $218K, exceeding expectations. Shares rose 8.23% after-hours. The company is expanding into new markets and therapies, with improved profitability and raised full-year margin guidance.
The earnings beat and updated guidance could lift the stock.
Insider open-market buying by the Chief Commercial Officer is a modest bullish signal, but it is not a fundamental catalyst by itself.
Earnings call transcript discloses improving profitability and a new connected-monitoring technology acquisition, supporting a near-term re-rating of growth and margin trajectory.
Guidance narrowing plus higher gross margin and a Phesgo US FDA 510(k) withdrawal shift the near-term revenue mix and risk profile.
AlphAI scores every news story that mentions KRMD with an AI model for sentiment and relevance, and aggregates insider trades from KORU Medical Systems, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
KORU Medical Systems (NYSE:KORU) reported Q3 2026 revenue of $11.6M, up 11% YoY, with gross margin expanding to 65.2%. Net income turned positive at $218K, exceeding expectations. Shares rose 8.23% after-hours. The company is expanding into new markets and therapies, with improved profitability and raised full-year margin guidance.
KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 KORU Medical Systems Announces Third Quarter 2026 Results Including Second Consecutive Quarter of Positive Net Income and Adjusted EBITDA MAHWAH, NJ – November 10, 2026 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical t
KALBERMATTEN ADAM R (Chief Commercial Officer) purchased 32,000 shares of KORU Medical Systems, Inc. (KRMD) at $3.16 ($0.10M total) on 2026-09-08.
KORU (KRMD) held its Q2 2026 earnings call, saying revenue was $12 million, up 18% for the quarter and 20% for the first half. The company reported gross margin up nearly 200 bps versus its 2026 range and positive net income for the first time since 2019. It discussed growth in domestic and international markets and a connected monitoring technology acquisition.
KORU Medical Systems reported Q2 2026 revenue up 18% and first positive net income since 2019, with domestic revenue up 12% and international revenue up 59%. It withdrew a US FDA 510(k) for Phesgo, narrowed FY revenue guidance to $47.5M-$48.5M, raised gross margin to 62%-64%, and expects positive adjusted EBITDA in 2026.
KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance MAHWAH, NJ – August 5, 2026 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development,
KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10 2 ex_10-1.htm AMENDMENT NO. 1 TO AMENDED & RESTATED MANUFACTURING & SUPPLY AGREEMENT Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND THE EXC
KALBERMATTEN ADAM R (President-Chief Commercial Off) purchased 12,500 shares of KORU Medical Systems, Inc. (KRMD) at an average of $3.94 ($3.93–$3.96) across 2 trades on 2026-06-11.
KORU Medical Systems, Inc. (NASDAQ:KRMD) published its slide deck in conjunction with its 2026 Q1 earnings call. This presentation provides details discussed during the call for investors and interested parties. The content was prepared by Seeking Alpha's transcripts team.
KORU Medical Systems announced strong first-quarter 2026 financial results, with net revenues increasing by 22% and gross profit by 20%. The company reiterated its full-year 2026 guidance, expecting continued growth in net revenues and positive adjusted EBITDA. Notably, KORU submitted a 510(k) application for its Freedom Infusion System for use with Deferoxamine, and two of its non-Ig pharma collaborations have advanced to Phase III clinical trials, highlighting its expansion into new drug categories and therapy areas.
